Status:

COMPLETED

Comparison of Long- and Short-acting Diuretics in Congestive Heart Failure

Lead Sponsor:

Hyogo Medical University

Collaborating Sponsors:

Ministry of Health, Labour and Welfare, Japan

Conditions:

Congestive Heart Failure

Eligibility:

All Genders

20+ years

Phase:

PHASE4

Brief Summary

The purpose of this study is to compare therapeutic effects of furosemide, a short-acting loop diuretic, and azosemide, a long-acting one, in patients with heart failure, and to test our hypothesis th...

Detailed Description

The mortality and morbidity of heart failure are still high despite emerging evidences that have shown beneficial effects of ACE inhibitor, beta-blocker, ARB, and aldosterone receptor antagonist. Diur...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of heart failure based on a slight modification of the Framingham criteria as previously described within 6 months before the entry
  • Current status of heart failure is NYHA II or III.
  • Currently, loop diuretic(s) is (are) administered.
  • No change in baseline therapy and symptoms of heart failure within a month

Exclusion

  • Current symptomatic hypotension
  • Hypertension that has not been controlled to the satisfaction of the investigator
  • Hemodynamically significant (in the investigators opinion) LV outflow tract obstruction (due to either aortic stenosis or ventricular hypertrophy)
  • Acute coronary syndrome
  • Primary pulmonary hypertension or pulmonary hypertension not due to LV dysfunction
  • Serious cerebrovascular disease
  • Acute myocardial infarction within the last 3 months
  • Patients who require intravenous inotropes
  • Cerebrovascular accident within the last 3 months
  • Percutaneous coronary intervention or open heart surgery within the last 3 months
  • On the waiting list for percutaneous coronary intervention or open heart surgery
  • Serum creatinine \> 2.5 mg/dl
  • Serious liver disease
  • Any change in cardiovascular drug therapy within a month prior to randomization
  • History of chronic obstructive pulmonary disease or restrictive lung disease
  • Diabetes mellitus that has not been well controlled (fasting blood glucose\>200 mg/dl、HbA1c \> 8%)
  • Any life-threatening acute disease
  • Patients with implantable cardiac defibrillator
  • Other diseases likely to cause death or serious disability during the period of the study
  • Patients unable to walk without personal aid

Key Trial Info

Start Date :

June 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2010

Estimated Enrollment :

320 Patients enrolled

Trial Details

Trial ID

NCT00355667

Start Date

June 1 2006

End Date

August 1 2010

Last Update

August 18 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Hospital of Hyogo College of Medicine

Nishinomiya, Hyōgo, Japan, 663-8501